Viral lung infections: Epidemiology, virology, clinical features, and management of avian influenza A(H7N9)

Current Opinion in Pulmonary Medicine

Volumn 20, Issue 3, 2014, Pages 225-232

  To, Kelvin K W ^a   Chan, Jasper F W ^a   Yuen, Kwok Yung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

avian influenza H7N9; clinical; diagnosis; pathology; treatment

Indexed keywords

ADAMANTANE; CORTICOSTEROID; FAVIPIRAVIR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; OSELTAMIVIR; RNA DIRECTED DNA POLYMERASE; SIALIDASE INHIBITOR; ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE; ZANAMIVIR;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIVIRAL THERAPY; AVIAN INFLUENZA; CLINICAL FEATURE; DISEASE SEVERITY; EPIDEMIC; HONG KONG; HUMAN; IMMUNOGENICITY; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INFLUENZA A (H7N9); INFLUENZA VIRUS A H7N9; LUNG BIOPSY; LUNG INFECTION; MULTIPLE ORGAN FAILURE; NASOPHARYNGEAL ASPIRATION; NONHUMAN; PERSONAL HYGIENE; PHYLOGENY; POULTRY; REVIEW; SPUTUM; SURVIVAL; VIROLOGY; VIRUS DIAGNOSIS; VIRUS LIKE AGENT; VIRUS PATHOGENESIS; VIRUS PNEUMONIA; VIRUS RESISTANCE; VIRUS SHEDDING; VIRUS TRANSMISSION; ANIMAL; ANTAGONISTS AND INHIBITORS; CATERING SERVICE; CHINA; COMMERCIAL PHENOMENA; COMMUNICABLE DISEASES, EMERGING; DISEASE OUTBREAKS; EPIDEMIOLOGY; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; MULTIDRUG RESISTANCE; PATHOGENICITY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TAIWAN; TRANSMISSION; ZOONOSIS;

ANIMALS; ANTIVIRAL AGENTS; CHINA; COMMERCE; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES, EMERGING; DISEASE OUTBREAKS; DRUG RESISTANCE, MULTIPLE, VIRAL; ENZYME INHIBITORS; FOOD SUPPLY; HONG KONG; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; NEURAMINIDASE; POULTRY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAIWAN; ZANAMIVIR; ZOONOSES;

EID: 84897580893     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000047     Document Type: Review

References (91)

1. Alexander DJ. Avian influenza viruses and human health. Dev Biol (Basel) 2006; 124:77-84.
2. Yuen KY, Chan PK, Peiris M, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998; 351:467-471.
3. World Health Organization. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2013. http://www. who.int/influenza/human-animal-interface/EN-GIP-20131008Cumulative NumberH5N1cases.pdf. [Accessed 25 November 2013]
4. Koopmans M, Wilbrink B, Conyn M, et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004; 363:587-593.
5. Chan JF, To KK, Tse H, et al. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol 2013; 21:544-555.
6. To KK, Ng KH, Que TL, et al. Avian influenza A H5N1 virus: a continuous threat to humans. Emerg Microbes Infect 2012; 1:e25.
7. Yuan J, Zhang L, Kan X, et al. Origin and molecular characteristics of a novel 2013 avian influenza A(H6N1) virus causing human infection in Taiwan. Clin Infect Dis 2013; 57:1367-1368.
8. Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368:1888-1897.
9. Chen Y, Liang W, Yang S, et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet 2013; 381:1916-1925
10. Yang F, Wang J, Jiang L, et al. A fatal case caused by novel H7N9 avian influenza A virus in China. Emerg Microbes Infect 2013; 2:e19.
11. Jie Z, Xie J, He Z, et al. Family outbreak of severe pneumonia induced by H7N9 infection. Am J Respir Crit Care Med 2013; 188:114-115.
12. European Centre for Disease Prevention and Control. Rapid risk assessment. Human infection with avian influenza A viruses, China. 24 February 2014. Stockholm: ECDC; 2014.
13. To KK, Song W, Lau SY, et al. Unique reassortant of influenza A(H7N9) virus associated with severe disease emerging in Hong Kong. J Infect 2014. [Epub ahead of print]
14. Ho PL, Sin WC, Chan JF, et al. Severe influenza A H7N9 pneumonia with rapid virological response to intravenous zanamivir. Eur Resp J 2014. (in press).
15. Chen H, Yuan H, Gao R, et al. Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. Lancet 2014; 383:714-721.
16. To KK, Tsang AK, Chan JF, et al. Emergence in China of human disease due to avian influenza A(H10N8): cause for concern? J Infect 2014; 68:205-215.
17. To KK, Chan JF, Chen H, et al. The emergence of influenza A H7N9 in human beings 16 years after influenza A H5N1: a tale of two cities. Lancet Infect Dis 2013; 13:809-821.
18. Lin PH, Chao TL, Kuo SW, et al. Virological, serological, and antiviral studies in an imported human case of avian influenza A(H7N9) virus in Taiwan. Clin Infect Dis 2014; 58:242-246.
19. Chang SY, Lin PH, Tsai JC, et al. The first case of H7N9 influenza in Taiwan. Lancet 2013; 381:1621.
20. Cowling BJ, Jin L, Lau EH, et al. Comparative epidemiology of human infections with avian influenza A H7N9 and H5N1 viruses in China: a population-based study of laboratory-confirmed cases. Lancet 2013; 382:129-137.
21. Chen E, Chen Y, Fu L, et al. Human infection with avian influenza A(H7N9) virus re-emerges in China in winter 2013. Euro Surveill 2013; 18:20616.
22. Dudley JP, Mackay IM. Age-specific and sex-specific morbidity and mortality from avian influenza A(H7N9). J Clin Virol 2013; 58:568-570.
23. Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 368:2277-2285.
24. Yu H, Cowling BJ, Feng L, et al. Human infection with avian influenza A H7N9 virus: an assessment of clinical severity. Lancet 2013; 382:138-145.
25. Liu S, Sun J, Cai J, et al. Epidemiological, clinical and viral characteristics of fatal cases of human avian influenza A (H7N9) virus in Zhejiang Province, China. J Infect 2013; 67:595-605.
26. Chen X, Yang Z, Lu Y, et al. Clinical features and factors associated with outcomes of patients infected with a novel influenza A (H7N9) virus: a preliminary study. PLoS One 2013; 8:e73362.
27. Li Q, Zhou L, Zhou M, et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China. N Engl J Med 2014; 370:520-532.
28. Wang C, Wang J, Su W, et al. Relationship between domestic and wild birds in live poultry market and a novel human H7N9 virus in China. J Infect Dis 2014; 209:34-37.
29. Bao CJ, Cui LB, Zhou MH, et al. Live-animal markets and influenza A (H7N9) virus infection. N Engl J Med 2013; 368:2337-2339.
30. Li J, Yu X, Pu X, et al. Environmental connections of novel avian-origin H7N9 influenza virus infection and virus adaptation to the human. Sci China Life Sci 2013; 56:485-492.
31. Zhang Q, Shi J, Deng G, et al. H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science 2013; 341:410-414.
32. Ai J, Huang Y, Xu K, et al. Case-control study of risk factors for human infection with influenza A(H7N9) virus in Jiangsu Province, China, 2013. Euro Surveill 2013; 18:20510.
33. Fang LQ, Li XL, Liu K, et al. Mapping spread and risk of avian influenza A (H7N9) in China. Sci Rep 2013; 3:2722.
34. Qi X, Qian YH, Bao CJ, et al. Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013 epidemiological investigation. BMJ 2013; 347:f4752.
35. Richard M, Schrauwen EJ, de Graaf M, et al. Limited airborne transmission of H7N9 influenza A virus between ferrets. Nature 2013; 501:560-563.
36. Xu L, Bao L, Deng W, et al. Novel avian-origin human influenza A(H7N9) can be transmitted between ferrets via respiratory droplets. J Infect Dis 2014; 209:551-556.
37. Watanabe T, Kiso M, Fukuyama S, et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature 2013; 501:551-555.
38. Zhu H, Wang D, Kelvin DJ, et al. Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science 2013; 341:183-186.
39. Gabbard JD, Dlugolenski D, Van Riel D, et al. Novel H7N9 influenza virus shows low infectious dose, high growth and efficient contact transmission in the guinea pig model. J Virol 2014; 88:1502-1512.
40. Belser JA, Gustin KM, Pearce MB, et al. Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice. Nature 2013; 501:556-559.
41. Lebarbenchon C, Brown JD, Stallknecht DE. Evolution of influenza A virus H7 and N9 subtypes, Eastern Asia. Emerg Infect Dis 2013; 19:1635-1638.
42. Xiong C, Zhang Z, Jiang Q, Chen Y. Evolutionary characteristics of A/Hangzhou/1/2013 and source of avian influenza virus H7N9 subtype in China. Clin Infect Dis 2013; 57:622-624.
43. Lam TT, Wang J, Shen Y, et al. The genesis and source of the H7N9 influenza viruses causing human infections in China. Nature 2013; 502:241-244.
44. Liu D, Shi W, Shi Y, et al. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet 2013; 381:1926-1932.
45. Wu A, Su C, Wang D, et al. Sequential reassortments underlie diverse influenza H7N9 genotypes in China. Cell Host Microbe 2013; 14:446-452.
46. Knepper J, Schierhorn KL, Becher A, et al. The novel human influenza A(H7N9) virus is naturally adapted to efficient growth in human lung tissue. MBio 2013; 4:e00601-13.
47. Zhou J, Wang D, Gao R, et al. Biological features of novel avian influenza A (H7N9) virus. Nature 2013; 499:500-503.
48. van Riel D, Leijten LM, de Graaf M, et al. Novel avian-origin influenza A (H7N9) virus attaches to epithelium in both upper and lower respiratory tract of humans. Am J Pathol 2013; 183:1137-1143.
49. Tharakaraman K, Jayaraman A, Raman R, et al. Glycan receptor binding of the influenza a virus H7N9 hemagglutinin. Cell 2013; 153:1486-1493.
50. Shinya K, Ebina M, Yamada S, et al. Avian flu: influenza virus receptors in the human airway. Nature 2006; 440:435-436.
51. Dortmans JC, Dekkers J, Wickramasinghe IN, et al. Adaptation of novel H7N9 influenza A virus to human receptors. Sci Rep 2013; 3:3058.
52. Xiong X, Martin SR, Haire LF, et al. Receptor binding by an H7N9 influenza virus from humans. Nature 2013; 499:496-499.
53. Yu L, Wang Z, Chen Y, et al. Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A(H7N9) virus. Clin Infect Dis 2013; 57:1449-1457.
54. Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 381:2273-2279.
55. Xu L, Bao L, Deng W, et al. The mouse and ferret models for studying the novel avian-origin human influenza A (H7N9) virus. Virol J 2013; 10:253.
56. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:1203-1207.
57. To KK, Hung IF, Li IW, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010; 50:850-859.
58. Cheng VC, To KK, Tse H, et al. Two years after pandemic influenza A/2009/H1N1: what have we learned? Clin Microbiol Rev 2012; 25:223-263.
59. Cheng VC, Chan JF, To KK, Yuen KY. Clinical management and infection control of SARS: lessons learned. Antiviral Res 2013; 100:407-419.
60. Chan JF, Li KS, To KK, et al. Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic? J Infect 2012; 65:477-489.
61. Shi J, Xie J, He Z, et al. A detailed epidemiological and clinical description of 6 human cases of avian-origin influenza A (H7N9) virus infection in Shanghai. PLoS One 2013; 8:e77651.
62. Wang Q, Zhang Z, Shi Y, Jiang Y. Emerging H7N9 influenza A (novel reassortant avian-origin) pneumonia: radiologic findings. Radiology 2013; 268:882-889.
63. Xu C, Havers F, Wang L, et al. Monitoring avian influenza A(H7N9) virus through national influenza-like illness surveillance, China. Emerg Infect Dis 2013; 19:1289-1292.
64. Ip DK, Liao Q, Wu P, et al. Detection of mild to moderate influenza A/H7N9 infection by China's national sentinel surveillance system for influenza-like illness: case series. BMJ 2013; 346:f3693.
65. Mei Z, Lu S, Wu X, et al. Avian influenza A(H7N9) virus infections, Shanghai, China. Emerg Infect Dis 2013; 19:1179-1181.
66. Lv H, Han J, Zhang P, et al. Mild illness in avian influenza A(H7N9) virusinfected poultry worker, Huzhou, China, April 2013. Emerg Infect Dis 2013; 19:1885-1888.
67. Yu X, Zhang X, He Y, et al. Mild infection of a novel H7N9 avian influenza virus in children in Shanghai. Emerg Microbes Infect 2013; 2:e41.
68. Yang P, Pang X, Deng Y, et al. Surveillance for avian influenza A(H7N9), Beijing, China, 2013. Emerg Infect Dis 2013; 19:2041-2043.
69. Yang S, Chen Y, Cui D, et al. Avian-origin influenza A(H7N9) infection in influenza A(H7N9)-affected areas of China: a serological study. J Infect Dis 2014; 209:265-269.
70. Bai T, Zhou J, Shu Y. Serologic study for influenza A (H7N9) among high-risk groups in China. N Engl J Med 2013; 368:2339-2340.
71. Hatchette TF, Drews SJ, Bastien N, et al. Detection of influenza H7N9 virus: all molecular tests are not equal. J Clin Microbiol 2013; 51:3835-3838.
72. Chan KH, To KK, Chan JF, et al. Analytical sensitivity of seven point-of-care influenza virus detection tests and two molecular tests for detection of avian origin H7N9 and swine origin H3N2 variant influenza A viruses. J Clin Microbiol 2013; 51:3160-3161.
73. Baas C, Barr IG, Fouchier RA, et al. A comparison of rapid point-of-care tests for the detection of avian influenza A(H7N9) virus, 2013. Euro Surveill 2013; 18:20487.
74. Qi Y, Fan H, Qi X, et al. A novel pyrosequencing assay for the detection of neuraminidase inhibitor resistance-conferring mutations among clinical isolates of avian H7N9 influenza virus. Virus Res 2014; 179:119-124.
75. Chan KH, To KK, Chan BW, et al. Comparison of pyrosequencing, Sanger sequencing, and melting curve analysis for detection of low-frequency macrolide-resistant mycoplasma pneumoniae quasispecies in respiratory specimens. J Clin Microbiol 2013; 51:2592-2598.
76. Yen HL, McKimm-Breschkin JL, Choy KT, et al. Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population. MBio 2013; 4:e00396-13.
77. Zhu Y, Qi X, Cui L, et al. Human co-infection with novel avian influenza A H7N9 and influenza A H3N2 viruses in Jiangsu province, China. Lancet 2013; 381:2134.
78. Li IW, Hung IF, To KK, et al. The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. Chest 2010; 137:759-768.
79. Fry AM, Goswami D, Nahar K, et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis 2014; 14:109-118.
80. Liu X, Li T, Zheng Y, et al. Poor responses to oseltamivir treatment in a patient with influenza A (H7N9) virus infection. Emerg Microbes Infect 2013; 2:e27.
81. Baranovich T, Burnham AJ, Marathe BM, et al. The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome. J Infect Dis 2013. [Epub ahead of print]
82. Wu Y, Bi Y, Vavricka CJ, et al. Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses. Cell Res 2013; 23:1347-1355.
83. Sleeman K, Guo Z, Barnes J, et al. R292K substitution and drug susceptibility of influenza A(H7N9) viruses. Emerg Infect Dis 2013; 19:1521-1524.
84. Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013; 100:446-454.
85. Hung IF, To KK, Lee CK, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 2013; 144:464-473.
86. Noah MA, Peek GJ, Finney SJ, et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA 2011; 306:1659-1668.
87. World Health Organization. China -WHO Joint Mission on Human Infection with Avian Influenza A(H7N9) Virus, 18-24 April 2013, Mission Report. http://www.who.int/influenza/human-animal-interface/influenza-h7n9/China H7N9JointMissionReport2013u.pdf. [Accessed 28 November 2013]
88. Yu H, Wu JT, Cowling BJ, et al. Effect of closure of live poultry markets on poultry-to-person transmission of avian influenza A H7N9 virus: an ecological study. Lancet 2014; 383:541-548.
89. Centers for Disease Control and Prevention. Interim Guidance for Infection Control Within Healthcare Settings When Caring for Patients with Confirmed, Probable, or Cases Under Investigation of Avian Influenza A(H7N9) Virus Infection. http://www.cdc.gov/flu/avianflu/h7n9-infection-control.htm. [Accessed 2 December 2013]
90. Fries LF, Smith GE, Glenn GM. A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med 2013; 369:2564-2566.
91. Chan JF, Lau SK, Woo PC. The emerging novel Middle East respiratory syndrome coronavirus: the 'knowns' and 'unknowns. J Formos Med Assoc 2013; 112:372-381.